Analyzing R&D Budgets: Grifols, S.A. vs Soleno Therapeutics, Inc.

R&D Spending: Grifols vs Soleno - A Decade of Innovation

__timestampGrifols, S.A.Soleno Therapeutics, Inc.
Wednesday, January 1, 20141807530002242216
Thursday, January 1, 20152241930004536244
Friday, January 1, 20161976170005184803
Sunday, January 1, 20172883200003068742
Monday, January 1, 20182406610007178000
Tuesday, January 1, 201927601800016267000
Wednesday, January 1, 202029421600023191000
Friday, January 1, 202135488100021453000
Saturday, January 1, 202236114000015265000
Sunday, January 1, 202333055100025189000
Loading chart...

Unleashing the power of data

The Evolution of R&D Investments: Grifols, S.A. vs Soleno Therapeutics, Inc.

In the competitive landscape of biotechnology, research and development (R&D) spending is a critical indicator of innovation and future growth. Over the past decade, Grifols, S.A. and Soleno Therapeutics, Inc. have demonstrated contrasting strategies in their R&D investments. From 2014 to 2023, Grifols, S.A. consistently increased its R&D budget, peaking in 2022 with a 100% increase from its 2014 levels. This robust investment underscores Grifols' commitment to advancing its product pipeline and maintaining its market leadership.

Conversely, Soleno Therapeutics, Inc., while showing a significant increase in R&D spending, particularly between 2019 and 2023, still operates on a much smaller scale. Their R&D expenses in 2023 were approximately 10% of Grifols' budget, highlighting the challenges smaller firms face in competing with industry giants. This disparity in R&D spending reflects broader trends in the biotech sector, where larger companies leverage their financial muscle to drive innovation.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025